Target intelligence / Profile preview

Herpesvirus helicase-primase complex (None established)

Target
None established
Molecular classification
Enzyme (multifunctional DNA-processing enzyme), Helicase (superfamily 1 DNA helicase: UL5 or pUL105), Primase (AEP superfamily primase: UL52 or pUL70)
01

Overview

The herpesvirus helicase-primase complex is a critical multi-enzyme assembly composed of three subunits: a helicase (e.g., UL5 in HSV-1, pUL105 in HCMV), a primase (e.g., UL52 in HSV-1, pUL70 in HCMV), and a noncatalytic accessory protein (UL8 in HSV-1, pUL102 in HCMV)[1][2][4][5]. The complex unwinds the viral double-stranded DNA and synthesizes short RNA primers required for DNA polymerase-mediated genome replication[1][2][3][5]. Both subunits are essential for viral genome propagation, and inhibitors targeting the helicase-primase are under clinical development for treatment of drug-resistant or recurrent herpesvirus infections[3][6][7]. This complex is highly conserved across the Herpesviridae family, although structural and sequence differences underlie drug sensitivity variation among viral species[4].

Other names
HSV-1 helicase-primase complexHerpes simplex virus helicase-primaseHerpesvirus DNA helicase/primase complexHelicase-primase (UL5/UL52/UL8 for HSV-1, pUL105/pUL70/pUL102 for HCMV)
02

Mechanism of action

Inhibition of helicase activity (blocks DNA strand unwinding); Inhibition of primase activity (prevents RNA primer synthesis for replication); Prevents viral DNA replication and proliferation

03

Biological functions

DNA replication (unwinding and priming template for DNA synthesis)Viral genome propagation
04

Disease associations

Infection (essential for herpesvirus replication: HSV, VZV, HCMV and others)
05

Safety considerations

Potential for off-target effects if host homologous enzymes are affected, though current drugs are selectiveEmergence of drug resistance mutations in viral complex subunitsTherapeutic specificity varies among herpesvirus subfamilies (e.g., pritelivir and amenamevir are not active against HCMV)
06

Interacting drugs

Pritelivir (BAY 57-1293)

3 more in the full profile.

07

Biomarkers

None established for direct patient selection or efficacy monitoring; resistance mutations in the UL5, UL52, or equivalent subunits may act as pharmacodynamic markers

Beyond the preview

Go deeper on Herpesvirus helicase-primase complex (None established).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpesvirus helicase-primase complex (None established).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call